Regional outcomes of severe acute respiratory syndrome coronavirus 2 infection in hospitalised patients with haematological malignancy.
Booth S. et al, (2020), Eur J Haematol, 105, 476 - 483
Fractures are common within 18 months following first-line R-CHOP in older patients with diffuse large B-cell lymphoma.
Booth S. et al, (2020), Blood Adv, 4, 4337 - 4346
Efficacy of central nervous system prophylaxis with stand-alone intrathecal chemotherapy in diffuse large B-cell lymphoma patients treated with anthracycline-based chemotherapy in the rituximab era: a systematic review.
Eyre TA. et al, (2020), Haematologica, 105, 1914 - 1924
Assessing the impact of lockdown: Fresh challenges for the care of haematology patients in the COVID-19 pandemic.
Willan J. et al, (2020), Br J Haematol, 189, e224 - e227
Care of haematology patients in a COVID-19 epidemic.
Willan J. et al, (2020), Br J Haematol, 189, 241 - 243
Escalated BEACOPDac as first line therapy in 100 Hodgkin lymphoma patients reduces red cell transfusion requirements and may shorten time to menstrual period recovery whilst maintaining efficacy compared to escalated BEACOPP
Santarsieri A. et al, (2020), BRITISH JOURNAL OF HAEMATOLOGY, 189, 97 - 99
Treatment of classical Hodgkin lymphoma in young adults aged 18-30 years with a modified paediatric Hodgkin lymphoma protocol. Results of a multicentre phase II clinical trial (CRUK/08/012).
Townsend W. et al, (2020), Br J Haematol, 189, 128 - 132
What do we know about duodenal-type follicular lymphoma? From pathological definition to treatment options.
Duffles Amarante G. et al, (2020), Br J Haematol, 188, 831 - 837
Development of a Novel Hematological Malignancy Specific Patient-Reported Outcome Measure (HM-PRO): Content Validity.
Goswami P. et al, (2020), Front Pharmacol, 11
Hematological Malignancy Specific Patient-Reported Outcome Measure (HM-PRO): Construct Validity Study.
Goswami P. et al, (2020), Front Pharmacol, 11
Quality-of-life issues and symptoms reported by patients living with haematological malignancy: a qualitative study.
Goswami P. et al, (2020), Ther Adv Hematol, 11
Reliability of a Novel Hematological Malignancy Specific Patient-Reported Outcome Measure: HM-PRO.
Goswami P. et al, (2020), Front Pharmacol, 11
Epstein-Barr Virus-Induced Cutaneous Diffuse Large B-Cell Lymphoma in a Patient With Angioimmunoblastic T-Cell Lymphoma.
Poon F. et al, (2019), Am J Dermatopathol, 41, 927 - 930
Population Pharmacokinetic Modeling and Exposure-Response Assessment for the Antibody-Drug Conjugate Brentuximab Vedotin in Hodgkin's Lymphoma in the Phase III ECHELON-1 Study.
Suri A. et al, (2019), Clin Pharmacol Ther, 106, 1268 - 1279
An International Multicentre Study of Consecutively Diagnosed Patients wSith ALCL: Outcomes Following First-Line Therapy in Routine Clinical Practice
Martinez-Calle N. et al, (2019), BLOOD, 134
Final Development of the First Generic Quality of Life and Symptoms Measure Specific for Hematological Malignancies: The HM-PRO
Goswami P. et al, (2019), BLOOD, 134
Follicular Lymphoma Frontline Immuno-Chemotherapy: Survival Outcomes and Infection-Related Morbidity
Djebbari F. et al, (2019), BLOOD, 134